Halozyme Therapeutics, Inc. (HALO) Misses Q4 EPS by 3c; Roche (RHHBY) Triggers $4M Milestone

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q4 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.41 million versus the consensus estimate of $5.25 million.

Roche (OTCBB: RHHBY) submission trigger $4 million milestone payment.

For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Helen of Troy rejects $37-per-share takeover bid from Spectrum Brands
• Netflix gains after Ackman endorsement and AI feature launch
• Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies